Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Cytokines are major regulators of innate and adaptive immunity that enable cells of the
immune system to communicate over short distances. Cytokine therapy to activate the …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are
recruited into the tumor site to fight against tumors. However, their small number and …

Hepatocellular carcinoma (HCC) is one of the world's deadliest and fastest-growing tumors,
with a poor prognosis. HCC develops in the context of chronic liver disease. Curative …

Immunotherapy plays an increasingly important role in the treatment of most malignant
tumors, and CD8+ T cells are the most important antitumor effector cells in the process of …

Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies
which redirect T cell specificity against a tumor-specific antigen through the use of antibody …

Liver cancer is the third leading cause of cancer death worldwide. Hepatocellular carcinoma
(HCC) is the most common primary malignant tumor of the liver. Liver resection or …

Simple Summary Hepatocellular carcinoma (HCC) is the most common liver malignancy
associated with poor prognosis. Treatment options are limited partially due to resistance to …